India’s Aurobindo buys Sandoz US assets from Novartis
The transaction underpins Novartis's strategy of achieving sustainable and profitable growth in the US in the long term.
Keystone
Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a $900 million (CHF870 million) cash payment.
This content was published on
2 minutes
A possible performance-related payment of $100 million could be added to the purchase price, the Swiss AWP financial news agency reported.
The divested business generated sales of $600 million in the first half of 2018. It includes approximately 300 products and development projects.
A Novartis spokesman refused to comment on whether other parts of the Sandoz portfolio in the United States were still for sale.
750 employees affected
The production facilities in Wilson, North Carolina, as well as in Hicksville and Melville, New York, will also be transferred to Aurobindo.
In this context, approximately 750 employees and the sales force of the dermatology business PharmaDerm will be transferred to the Indian company upon completion of the transaction.
Novartis said the transaction is expected to close during 2019.
Focus on complex generics
Sandoz will focus instead on complex generics, value-added medicines and biosimilars.
The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. “With this transaction, we are focusing our business,” Sandoz CEO Richard Francis was quoted as saying.
The Sandoz portfolio will remain “strong” even after the transaction, according to the company statement. It includes injectables, respiratory products and ophthalmics.
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
The image of foreigners in Switzerland has deteriorated
This content was published on
The Federal Statistical Office has found that Swiss people’s views of foreigners have worsened over the last couple of years.
After mild winter, nature wakes up earlier in Switzerland
This content was published on
Once again this year, nature has woken up earlier than normal, between a week and ten days ahead of schedule due to a mild winter.
Computer failure disrupts air traffic at Geneva airport
This content was published on
A computer breakdown has disrupted operations at Geneva Airport since midday on Tuesday. Significant delays are expected.
Swiss show high willingness to pay for sustainable flats
This content was published on
Tenants in Switzerland are in favour of sustainable flats. However, the willingness to pay differs by income according to a new study.
Swiss customs intercepted over 200 tonnes of smuggled meat in 2024
This content was published on
The Federal Office for Customs and Border Security intercepted around 208 tonnes of smuggled meat at border crossings in 2024.
Switzerland faces infrastructure gaps for CO2 capture
This content was published on
Switzerland must actively remove CO2 from the air in order to become climate-neutral by 2050. However, the infrastructure for this isn't sufficient.
Swiss parliament prohibits sale of Swiss space company Beyond Gravity
This content was published on
The Swiss parliament has said that the Swiss government should not sell the Swiss space company Beyond Gravity, which is part of RUAG.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis chief hints at job cuts in Switzerland
This content was published on
The president of pharmaceutical giant Novartis has announced job cuts in an interview with Swiss newspaper NZZ am Sonntag.
This content was published on
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time…
Eye on the Multinationals: Your questions become our stories
This content was published on
Do you work for or would like to work for a multinational company? Are you concerned about the impact of multinational companies at home and abroad?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.